Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
| Autor: | Sigrid Klaar, Lars Larsson, Jenny Andersson, Göran Carlsson, John Ohd, Jonas Bergh, Bengt Gustavsson, Jan Nilsson, Mats Inganäs, Lars Holmberg, C-M. Rudenstam |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Genetic Markers Oncology medicine.medical_specialty Neoplasms Hormone-Dependent Cyclophosphamide Breast Neoplasms Polymerase Chain Reaction Risk Assessment Sensitivity and Specificity Cohort Studies Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans skin and connective tissue diseases Lymph node Aged Neoplasm Staging Probability Retrospective Studies Aged 80 and over Univariate analysis business.industry Hematology Middle Aged Genes p53 Prognosis Antiestrogen medicine.disease Survival Analysis Surgery Gene Expression Regulation Neoplastic Tamoxifen Methotrexate medicine.anatomical_structure Chemotherapy Adjuvant Mutation Female Fluorouracil Cisplatin business medicine.drug |
| Zdroj: | Annals of Oncology. 16:743-748 |
| ISSN: | 0923-7534 |
| Popis: | Background: TP53 has been described as a prognostic factor in many malignancies, including breast cancer. Whether it also might be a predictive factor with reference to chemo- and endocrine therapy is more controversial. Patients and methods: We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received polychemotherapy [cyclophosphamide, methotrexate, 5-fluorouracil (CMF)] and/or endocrine therapy (tamoxifen). Sequence analyses of the whole TP53 coding region was performed in 376 patients operated on for primary breast cancer with axillary lymph node metastases between 1984 and 1989 (median follow-up time 84 months). Results: TP53 mutations were found in 105 patients (28%). We found 90 (82%) of the 110 mutations in the more frequently analysed exons 5 – 8, while the other 20 (18%) were located in exons 3 – 4 and 9 – 10, respectively. Univariate analyses showed TP53 to be a significant prognostic factor with regard to RFS, BCCS and OS in patients who received adjuvant CMF. Conclusions: TP53 mutations might induce resistance to certain modalities of breast cancer therapy. Sequence-determined TP53 mutation was of negative prognostic value in the total patient population |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|